Brief: Kineta Publishes Preclinical Data Demonstrating The Potential Of Anti-VISTA Antibody KVA12123
13/12/2023 13:42
Dec 13 (Reuters) - Kineta Inc KA.O :
* KINETA PUBLISHES PRECLINICAL DATA DEMONSTRATING THE
POTENTIAL OF
ANTI-VISTA ANTIBODY KVA12123 AS AN IMMUNOMODULATORY THERAPY FOR
CANCER
* KINETA INC - KVA12123 RECOGNIZES A UNIQUE VISTA EPITOPE
AND
BINDS AT NEUTRAL AND ACIDIC PH
* KINETA INC - DATA SUPPORTS KVA12123'S POTENTIAL AS A
THERAPY
AGAINST POORLY IMMUNOGENIC TUMORS
Source text for Eikon: ID:nGNX3Krhy1
Further company coverage: KA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kineta
See all newsBrief: TuHURA Biosciences And Kineta Stockholders Approve Proposed Merger And All Related Proposals
Brief: Kineta Updates KVA12123 Clinical Results From Ongoing Phase 1/2 Vista101 Study At Society For Immunotherapy Of Cancer
U.S. STOCKS ON THE MOVE-Copper miners, Palo Alto Networks, Lowe's
U.S. STOCKS ON THE MOVE-Lineage, J.B. Hunt, McDonald's
Kineta rises on resuming enrollment in early-stage cancer study